Key secondary end points ( radiographic progression-free survival -LSB- rPFS -RSB- , @ % decrease of prostate-specific antigen -LSB- PSA@ -RSB- , and pain response at @ weeks ) were to undergo statistical testing only if the primary end point analysis was significant .